Asana Medical, now known as Regentys Corporation, is pioneering the development of the ExtraCellular Matrix Hydrogel (ECMH), a novel therapeutic approach for treating Ulcerative Colitis (UC). This first-in-class, non-surgical treatment utilizes a proprietary extracellular matrix technology derived from porcine small intestine submucosa. The ECMH is designed to be administered rectally, where it transforms into a gel upon reaching body temperature, effectively coating the mucosal lining of the gastrointestinal tract. This gel acts as a bio-scaffold, providing a physical barrier that supports the natural healing process of damaged tissues, thereby promoting rapid tissue regeneration and reducing inflammation.

Regentys has secured European patent protection for its ECMH technology, which not only addresses UC but also has potential applications for other inflammatory bowel diseases, such as Crohn's Disease. The company has conducted multiple preclinical studies demonstrating the efficacy of ECMH in restoring cell barrier function and alleviating clinical symptoms associated with UC. With plans to initiate human trials, Regentys aims to offer a targeted, non-surgical alternative to existing treatments, which often involve immunosuppressive therapies or surgical interventions, thereby improving the quality of life for patients suffering from these debilitating gastrointestinal disorders.

United States

Asana Medical focuses on the development and commercialization of medical devices for gastrointestinal applications.

Asana Medical(Regentys)

Company Details